{
    "success": true,
    "data": {
        "complex": true,
        "leverage": true,
        "derivates": true,
        "swaps": true,
        "inverse": false,
        "replication_method": "synthethic",
        "ucits": false,
        "type": "ETP",
        "complex_factors": [
            "Leverage (3x daily return)",
            "Swap usage (with Natixis)",
            "Complexity of replication method (synthetic)"
        ],
        "classification": "complex",
        "supporting_data": "The product, 'GraniteShares 3x Long Moderna Daily ETP Securities', seeks to replicate 3 times the daily performance of Moderna.  Crucially, it's backed by a swap with Natixis, making it a synthetic replication strategy. This synthetic replication, combined with the 3x leverage, inherently introduces counterparty risk with Natixis.  The daily reset of the leverage factor and the potential for substantial deviation from a simple 3x multiplier on periods longer than a day due to compounding volatility introduce further complexities. The product's high risk indicator (7/7) suggests substantial market risk, but more importantly, the complex structure of the ETP and its reliance on derivatives makes it difficult for retail investors to understand the risks involved.  The KID explicitly states that the product is 'not simple and may be difficult to understand', which is a strong indicator of MiFID II complexity.  The reliance on a swap introduces collateral and counterparty risk, which are not easily digestible for the average investor."
    }
}